The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.
about
Brain morphometry and the neurobiology of levodopa-induced dyskinesias: current knowledge and future potential for translational pre-clinical neuroimaging studies.IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primatesBasal Ganglia disorders associated with imbalances in the striatal striosome and matrix compartments.Anatomy of Graft-induced Dyskinesias: Circuit Remodeling in the Parkinsonian StriatumManagement of impulse control disorders in Parkinson's disease: Controversies and future approachesOpioid system in L-DOPA-induced dyskinesia.The use of nonhuman primate models to understand processes in Parkinson's disease.Non-human primate models of PD to test novel therapies.Clinical features, pathophysiology, and treatment of levodopa-induced dyskinesias in Parkinson's disease.Long-term effect of sub-anesthetic ketamine in reducing L-DOPA-induced dyskinesias in a preclinical model.CNS penetration of the opioid glycopeptide MMP-2200: a microdialysis study.Psychosis After Switch in Opioid Maintenance Agonist and Risperidone-Induced Pisa Syndrome: Two Critical Incidents in Dual Diagnosis Treatment.Dual κ-agonist/μ-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease.
P2860
Q30833645-998AFE8B-FCCD-447E-91A5-A72A223E8F1BQ34542164-0FC3866E-C06D-4A3E-B41D-BB3CB3571704Q35208420-ED427C4D-6079-4441-94D4-ED3A07E2DBD5Q36034592-6946D657-DF3A-427D-8E5A-3055206FCD92Q37361959-793087AA-D2B6-47AC-A912-CFCC6DFBCED2Q37589209-02038FC1-D360-48AF-840A-D905745C91DCQ39208290-797400F7-A31D-4653-84B9-B17CDA5376C6Q39229450-E914F7EA-2788-460D-AEBC-100DEB283258Q41645312-98DE3662-7803-40A8-994D-30B7F7AE312AQ42106610-7D524672-35E2-4843-830B-73265EC94BE3Q42573127-BB7193DE-5D81-48B3-8851-4CEEBD89B44DQ44341865-9A5B705B-43A2-43B9-A559-B262DF79D59AQ44350349-7532CC2E-926F-49E1-9227-D4823FD5F431
P2860
The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
The selective mu-opioid recept ...... model of Parkinson's disease.
@en
The selective mu-opioid recept ...... model of Parkinson's disease.
@nl
type
label
The selective mu-opioid recept ...... model of Parkinson's disease.
@en
The selective mu-opioid recept ...... model of Parkinson's disease.
@nl
prefLabel
The selective mu-opioid recept ...... model of Parkinson's disease.
@en
The selective mu-opioid recept ...... model of Parkinson's disease.
@nl
P2093
P2860
P50
P921
P356
P1433
P1476
The selective mu-opioid recept ...... model of Parkinson's disease.
@en
P2093
Allan Goodman
Bertrand Le Bourdonnec
Diane L DeHaven-Hudkins
James B Koprich
Patrick J Little
Robert N DeHaven
Roland E Dolle
P2860
P304
P356
10.1002/MDS.23631
P407
P577
2011-04-04T00:00:00Z